✦ LIBER ✦

Taiwan funds three year R&D project

Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 39 KB
Volume: 16
Category: Article
ISSN: 0961-1290
DOI: 10.1016/s0961-1290(03)00780-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Global change encyclopedia: A project fo

Global change encyclopedia: A project for the International Space Year

✍ J. Cihlar; R. Simard; M. Manore; R. Baker; D. Clark; J. Kineman; J. Allen; M. Ru 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 472 KB

A three-year-old girl with a yolk sac tu

A three-year-old girl with a yolk sac tumor in the orbit/maxillary sinus

✍ Bresters, D. ;Zwaan, Ch. M. ;Veerman, A.J.P. ;Leemans, Ch. R. ;Westerveld, G.J. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 33 KB

Three-year relapse-free survival rates i

Three-year relapse-free survival rates in childhood rhabdomyosarcoma of the head and neck: Report from the intergroup rhabdomyosarcoma study

✍ Wataru W. Sutow; Robert D. Lindberg; Edmund A. Gehan; Abdelsalam H. Ragab; R. Be 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB 👁 2 views

Three-year recurrence-free survival in a

Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy

✍ Daniel Beutler; Pierino Avoledo; Jean-Claude Reubi; Helmut R. Mäcke; Jan Müller- 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

Evaluation of the worth of Corynebacteri

Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight-year results from the national surgical adjuvant breast and bowel project B-10

✍ Bernard Fisher; Ann Brown; Norman Wolmark; Edwin R. Fisher; Carol Redmond; D. La 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

During the 1970s, information obtained from animal tumor models and from patients with a spectrum of solid tumors indicated the worth of a variety of immunostimulating agents. These findings provided a biological and clinical rationale for conducting randomized trials to evaluate the worth of those

Risk of tuberculosis is higher with anti

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry

✍ F. Tubach; D. Salmon; P. Ravaud; Y. Allanore; P. Goupille; M. Bréban; B. Pallot- 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views